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Human papilllomaviruses (HPVs) are common human pathogens that infect cutaneous or mucosal
epithelia in which they cause warts, self-contained benign lesions that commonly regress. The HPV life
cycle is intricately tied to the differentiation of the host epithelium it infects. Mucosotropic HPVs are the
most common sexually transmitted pathogen known to mankind. A subset of the mucosotropic HPVs, so-
called high risk HPVs, is etiologically associated with numerous cancers of the anogenital tract, most
notably the cervix, as well as a growing fraction of head and neck cancers. In these cancers, the HPV
genome, which normally exists an a double stranded, circular, nuclear plasmid, is commonly found
integrated into the host genome and expresses two viral oncogenes, E6 and E7, that are implicated in the
development and maintainance of the cancers caused by these high risk HPVs. Numerous studies,
primarily on the high risk HPV16, have documented that the methylation status of the viral genome
changes not only in the context of the viral life cycle but also in the context of the progressive neoplastic
disease that culminates in cancer. In this article, we summarize the knowledge gained from those studies.
We also provide the ﬁrst analysis of available ChIP-seq data on the occupancy of both epigentically
modiﬁed histones as well as transcription factors on the high risk HPV18 genome in the context of HeLa
cells, a cervical cancer-derived cell line that has been the subject of extensive analyses using this
technique.
& 2013 Elsevier Inc. All rights reserved.Introduction
A number of studies have investigated the methylation status of
the human papillomavirus genome both in the context of the viral
life cycle and associated neoplastic disease (summarized in Table 1).
Most of these studies have focused on the high risk HPV most
commonly associated with human cancer, HPV16, with a few
studies looking at other high risk HPVs. Until recently, studies have
focused on evaluating the methylation status of the HPV long
control region (LCR; also referred to as the upstream regulatory
region or URR) which contains the viral promoter driving expres-
sion of early genes including the viral oncogenes E6 and E7 that are
frequently found expressed in HPV-associated neoplastic disease
including cancers, the viral transcriptional enhancer, and the viral
origin of DNA replication. Also commonly analyzed are regions
neighboring the LCR on the circular double stranded DNA genome,
including the 3′ region of L1, which is upstream of the LCR, and the
E6 gene, which is downstream of the LCR. Studies have employed
the use of methylation-sensitive restriction endonucleases and/orll rights reserved.
er Research, 1400 University
.bisulﬁte treatment to distinguish methylated from unmethylated
cytosines. In the latter case, the standard approach has been to PCR
amplify bisulﬁte-treated DNA using regional speciﬁc primers
followed by sequencing of the amplimer products directly or after
cloning (the latter having the advantage that one identiﬁes the
methylation status of individual copies of the viral genome as
opposed to the average methylation state of multiple genomes).
More recently deep sequencing technologies have been used to
interrogate the methylation status of bisulﬁte treated DNA, allowing
one to look at the whole viral genome, as opposed to speciﬁc PCR-
ampliﬁed regions. Table 1 lists these studies and provides a synopsis
of the methods used to analyze the methylation patterns, the
regions of the viral genome analyzed, and the major ﬁndings. In
addition to studies evaluating the methylation status of the viral
genome, recent chromatin-immunoprecipitation/sequencing (ChIP-
seq) analyses performed on HeLa cells, which were derived from an
HPV18-positive cervical cancer, have provided important new
insights into the epigenetic state and transcription factor occupancy
of human chromosomes. We now report the reanalysis of these
datasets to determine the histone modiﬁcation status as well as the
occupancy of host transcriptional machinery on the HPV18 genome
in these cancer cells.
The general conclusion that can be drawn from the studies listed
in Table 1 are that the methylation state of the papillomaviral DNA
Table 1
Papillomavirus genome methylation status.
Study Samples analyzed HPV genotype/state Region
analyzed
Method of analysis Methylation status
1. Kim et al. (2003) CIN lines (W12E) HPV16/
extrachromosomal
LCR Bisulﬁte/PCR/clone/
seq
Undif.: modest
Dif: none
2. Kalantari et al. (2008a) CIN lines (W12E/I) HPV16/
extrachromosomal
3′L1-LCR Bisulﬁte/PCR/clone/
seq
W12E undif: modest
HPV16/integrated W12E dif.: none
W12I type 1 undif: none
W12I type 1 dif: none
W12I type 2 undif: high
W12I type 2 dif: high
3. Badal et al. (2004) CC lines, exfoliated
cervical cells:
Multiple HPV
genotypes/ integrated or
not determined
-whole
genome for
RE analysis
HpaII/MspI and McrBC
RE digestion for whole
genome followed by
PCR
Shown are results from buisulﬁte seq:
-segments of
L2 and LCR
for bisulﬁte/
seq
SiHa (type 1): unmethylated LCR
Asymp - CC Bisulﬁte/PCR/seq for
segments of the HPV
genome
Caski (type 2): methylated LCR
Cancers: more frequently methylated LCR
Asymtomatic/CIN: more frequently unmethylated
LCR
4. Kalantari et al. (2004) Clinical cervical
samples of various
types and sources
HPV16/nd 3′L1-LCR Bisulﬁte/PCR/cloning/
seq
L1 more frequently methylated than the LCR
Cancers more highly methylated than precancers
Asymp - CC
5. Bhattacharjee and
Sengupta, (2006)
Exfoliated cells and
biopsies:
HPV16/nd LCR MS-restriction
digestion/PCR
No difference in overall methylation of LCR with
disease based upon MS-restriction digestion
method, but hype-rmethylation of E2BS found in
cancer based upon bisulﬁte/seq analysis.
Bisulﬁte/PCR/seq of
a subset of samples
Asymp, CC
6. Turan et al. (2006) CC line, FFPE
samples for CC,
exfoliated cervical
cells: Asymp - CC
HPV18/nd 3′L1-LCR Bisulﬁte/PCR/cloning/
seq
L1 more highly methylated in CC compared to
aymptomatic or CIN lesions
7. Kalantari et al. (2009) FFPE samples HPV16/nd 3′L1-LCR Bisulﬁte/PCR/cloning/
seq
L1 region hypermethylated in cancers, inconsistent
in normalCC, normal
adjacent (LCM)
8. Brandsma et al. (2009) Exfoliated cervical
cells:
HPV16/nd whole
genome
Bisulﬁte/PCR//seq hypermethylation in E2/L2 and L1 associated with
neoplastic progression to high grade CIN
Asymp – CIN3
9. Ding et al. (2009) CC cell lines, HPV16/nd LCR Bisulﬁte/PCR/cloning/
seq
Methylation was increased with neoplastic
progressionExfoliated cervical
cells:
LSIL - CC
10. Hublarova et al.
(2009)
Exfoliated cervical
cells:
HPV16/nd LCR MS-restriction
digestion/PCR
Increased methylation of LCR in patients with CIN/
cancer
Asymp - CC
11. Hong et al. (2008) Exfoliated cervical
cells:
HPV16/nd LCR Bisulﬁte/PCR/
pyrosequencing
Methylation was increased with neoplastic
progression
Asymp - CC
12. Sun et al. (2012) Exfoliated cervical
cells:
HPV16/nd L1-LCR Bisulﬁte/
pyrosequencing
Methylation in L1 increased in CIN3+
Bisulﬁte/EpityperAsymp - CC
13. Kalantari et al. (2010) Exfoliated cervical
cells:
HPV16/nd 3′L1-5′LCR Bisulﬁte/PCR/cloning/
seq
Inconsistent methylation of CpGs in 5′ LCR in CIN
lesions, most unmethylated
CIN
14. Mazumder Indra et al.
(2011)
Biopsies: HPV16/ mixture of
genomic states
determined by PCR of 5′
vs 3′ early region
LCR MS-restriction
digestion/PCR
LCR largely hypomethylated with exception of
promoter region in some samples with integrated
HPV16
CIN-CC
15. Snellenberg et al.
(2012)
Exfoliated cervical
cells, biopsies:
HPV16/nd LCR (E2BS
only)
Methylation
independent PCR,
luminex
E2BSs are more heavily methylated in cancers
CIN, CC
16. Vinokurova and von
Knebel Doeberitz
(2011)
FFPE samples: HPV16/ genomic status
determined by APOT
LCR Bisulﬁte/PCR/cloning/
seq
In CIN, saw 5′ LCR hypermethylated compared to 3′
LCR
Also COBRACIN, normal adjacent In tissue supporting life cycle, saw differential
methylation as a function of differentiation
17. Wentzensen et al.
(2012)
Exfoliated cervical
cells:
HPV18, HPV31, HPV45/
nd
Whole
genomes
Bisulﬁte/
pyrosequencing
Methylation increased in E2-L1 region of all 3 HPVs
in CIN3 compared to aymptomatic
Asymp, CIN3
18. Mirabello et al. (2013) Exfoliated cervical
cells:
HPV16/nd Whole
genome
Bisulﬁte/
pyrosequencing
Methylation in L1 associated with CIN2+ disease
and can be predictive of CIN2+ in pre-diagnostic
samplesAsymp - CC
19. Chaiwongkot et al.
(2013)
Biopsies: HPV16/ genomic status
determined by APOT
assay
LCR Bisulﬁte/
pyrosequencing
E2BS more hypermethylated in samples with
extrachromosomal HPV16CIN-CC
20. Xi et al. (2011) Exfoliated cervical
cells:
HPV16/nd LCR Bisulﬁte/PCR/cloning/
seq
Methylation in the 3′ end of LCR was observed more
in lower grade CIN
CINs
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Table 1 (continued )
Study Samples analyzed HPV genotype/state Region
analyzed
Method of analysis Methylation status
21. Patel et al. (2012) Exfoliated cervical
cells
HPV16/nd L1-LCR Bisulﬁte/
pyrosequencing
Hypomethylation of LCR associated abnormal
pathology
Asymp - HSIL
22. Piyathilake et al.
(2011)
Exfoliated cervical
cells
HPV16/nd LCR Bisulﬁte/
pyrosequencing
Hypomethylation of LCR associated with CIN2+
disease
CINs
23. Balderas-Loaeza
et al. (2007)
Primary tumor: HPV16/nd L1-LCR Bisulﬁte/PCR/clone/
seq
LCR hypomethylated in majority of HNCs
HNC L1 hypermethylated in HNCs;
24. Wiley et al. (2005) Anal swabs HPV16/nd LCR Bisulﬁte/PCR/clone/
seq
Heterogeneous patterns with promoter region more
hypermethylated in some cancers compared to AIN
samples
AIN-anal cancer
E. Johannsen, P.F. Lambert / Virology 445 (2013) 205–212 207genome is dynamic both in the context of the viral life cycle
and associated neoplastic disease. The latter point has led to the
suggestion that the methylation status of the HPV genome may be
diagnostic if not prognostic of neoplastic progression as detailed
below. That the methylation status is dynamic both in the context of
the viral life cycle and associated neoplastic progression supports
the hypothesis that epigenetic regulation of viral gene expression is
an important factor in HPV-associated disease. Another observation
is that the viral genome likely is subjected to de novo methylation
by host DNA methyltransferases (DNMTs) implicated in innate
responses to pathogens. Thus methylation of the viral genome
may be in part a mechanism by which the host attempts to
suppress viral gene expression and thereby HPV pathogenicity. In
the context of HeLa cells, we ﬁnd that there is also found localized
distinctions in the histone modiﬁcation status of the chromatin
assembled on the HPV18 genome that correlates with the occu-
pancy of host transcriptional machinery speciﬁcally within the LCR.
Intriguingly, the viral oncogenes modulate the epigenetic machin-
ery of the host through their interplay with both DNMT (Au Yeung
et al., 2010; Hsu et al., 2012; Laurson et al., 2010) as well as histone
modiﬁcation enzymes (Bodily et al., 2011; Hyland et al., 2011;
McLaughlin-Drubin et al., 2011). This interplay has implications
not only on the epigenetic regulation of the viral genome but also
the host genome, and may play an essential role both in the viral life
cycle and also associated neoplastic disease.
As part of the series of articles in this special issue of Virology
that are tied to the PAVE database, this article focuses on summar-
izing the knowledge gained from methylation and ChIP-seq ana-
lyses of HPV genomes. In the latter regard, we report the results of
our re-analysis of ChIP-seq data from studies performed on HeLa
cells to determine the occupancy of modiﬁed histones and tran-
scription factors on the HPV18 genome. Implications of this analysis
of ChIP-seq data on the epigenetic control of viral gene expression
are discussed. The reader is also directed to other recent reviews
focusing on the potential value of methylation analyses of the HPV
genome in diagnosing/predicting HPV-associated disease (Clarke
et al., 2012), and the epigenetics of the host chromosome in the
context of HPV-associated disease (Szalmas and Konya, 2009). This
article is divided into four parts: (1) the methylation status of the
viral genome in the context of the viral life cycle, (2) the methyla-
tion status of the viral genome in neoplastic progression, (3) the
inﬂuence of methylation status on the function of the viral E2
transcription factor, and (4) the analysis of ChIP-seq data from
studies performed on HeLa cells with regard to the HPV18 genome.
Methylation status of the viral genome in the context of the viral life
cycle
Kim et al. (2003) provided the ﬁrst analysis of the methylation
status of the HPV16 genome in the context of the viral life cycle.This study analyzed the methylation status of the LCR in a clonal
cell line, W12E, derived from an HPV16-positive CIN (Jeon et al.,
1995), that harbors the viral genome as an extrachromosomal
nuclear plasmid and that upon induction of differentiation sup-
ports the productive stage of the viral life cycle as evidenced by
the production of virus particles (Flores and Lambert, 1997). Their
analyses demonstrated that de novo host DNA methyltransferases
must be acting to modify the viral genome given the pattern of
cytosine methylation at not only CpG dinucleotides but other CpX
dinucleotides. They also learned, that upon induction of differ-
entiation, the viral LCR becomes hypomethylated, demonstrating
that the methylation status of the viral genome is dynamic. A more
recent study by Vinokurova and von Knebel Doeberitz (2011)
analyzed the methylation status of the HPV16 LCR in distinct
stages of the viral life cycle in patient derived tissues, using laser
microdissection to capture different layers of the epithelium
within the infectious lesions. They also found dynamic changes
in the methylation status of the HPV16 LCR in the context of the
viral life cycle; however with some differences in the nature of
those changes. Speciﬁcally, within the terminally differentiated
epithelial compartment that was supporting the late stages of the
viral life cycle as evidenced by capsid protein expression, they saw
a decrease in methylation in the transcriptional enhancer region
within the LCR, similar to what was observed in the earlier study.
But they also observed an increase in methylation within the
region of the LCR containing the early promoter. Interestingly
among the sites hypermethylated in the promoter region were
sites within the viral E2 transcription factor binding sites that are
thought to mediate transcriptional repression of the early promo-
ter. The implications of this observation are discussed in part 3.Methylation status of the viral genome in neoplastic progression
HPV-associated neoplasia is a progressive disease that has been
well deﬁned in the case of cervical carcinogenesis. High risk HPV
infections progress through different stages of precancerous
disease states, referred to as cervical intraepithelial neoplasia
(CIN) grades 1–3 associated with decreasing degrees of epithelial
differentiation and increasing degrees of dysplasia including the
accumulation of cells with enlarged nuclei. From CIN3 can arise
carcinomas or adenocarcinomas. The Pap smear is a commonly
utilized cytological assay designed to identify CINs before they can
progress to cancers, providing an effective means of intervention
in preventing cervical cancer. These common cytological prepara-
tions along with biopsies both from CINs that are obtained from
patients with positive Pap smears, and cervical cancers have
provided a rich source of clinical material that has been exploited
to perform epigenetic studies on high risk HPVs in the context of
neoplastic progression.
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regions of the HPV16 genome by sequencing of bisulﬁte treated
DNA ﬁrst observed that methylation within the 3- region of the L1
gene is associated with neoplastic progression: this region was
heavily methylated in cervical cancers but poorly methylated in
low grade CINs. These ﬁndings were validated by a number of
follow-up studies (Balderas-Loaeza et al., 2007; Kalantari et al.,
2010, 2009, 2008b) including two that evaluated the methylation
status of the whole genome (Brandsma et al., 2009; Hernandez
et al., 2012) in which hypermethylation of not only the HPV16 L1
gene but also the L2 and E5 genes were observed in more severe
neoplastic disease in the cervix. Mirabello et al. (2013) found
increased methylation in E2, L2, and L1 genes was associated with
increased risk of CIN3 in the context of serial sets of samples taken
fromwomen. Thus increases in methylation of the structural genes
and E2 may not only be diagnostic of high grade CIN and cancer
but also of potential prognostic value in predicting progression.
Changes in methylation within the LCR have also been seen as a
function of neoplastic progression; however, the direction of those
changes differ between studies. Badal et al. (2004) observed
decreased methylation of the LCR in HPV16-positive CINs com-
pared to HPV16-positve samples with normal cytology, an obser-
vation that has been reproduced in several other studies
(Hublarova et al., 2009; Mazumder Indra et al., 2011; Piyathilake
et al., 2011; Xi et al., 2011) that also included the evaluation of
cervical cancers. Whereas, others (Bhattacharjee and Sengupta,
2006; Ding et al., 2009; Hong et al., 2008) found increasing
methylation within the LCR in more advanced cervical neoplasia.
The reason for these disparities is not understood but may reﬂect
differences in the types of techniques used to analyze methylation
state of the viral genome and/or differences in the state of the viral
genome within lesions as discussed below.
It is potentially important to consider the interplay between
the viral genome's state within neoplasias and epigenetic regula-
tion of viral gene expression. During the viral life cycle the viral
genome is maintained as a circular, extrachromosomal, nuclear
plasmid. Here the viral E1 and E2 proteins play a critical role in the
replication and inheritance of the extrachromosomal viral genome
in the proliferating compartment of the infected epithelium
(McBride et al., 2006). E1 acts as a DNA helicase to unwind the
viral genome at the growing replication fork. E2, in addition to its
role as a transcription factor, recruits the E1 protein to the viral
genome to allow it to function as a viral genome-speciﬁc DNA
helicase, and functions to tether the viral genome to host chromo-
somes during cell division allowing for the efﬁcient inheritance of
the viral genome to daughter cells. During neoplastic progression,
the high risk HPV genomes often but not always are found to
become integrated into the host genome. Integration often arises
at fragile sites within the host genome, sites prone to undergoing
genetic recombination (Popescu and DiPaolo, 1990; Smith et al.,
1992). These recombination events commonly occur within the 3′
early region of the virus and often result in the deletion of part of
the viral genome 3′ to the recombination break point, with
continued if not enhanced expression of the two viral oncogenes
E6 and E7. Genes disrupted and/or deleted by the integration
events include E1, E2, E4, E5 and L2. One of these viral gene
products, E2, is known to repress transcription of the viral early
genes including the oncogenes E6 and E7 (Thierry and Howley,
1991). Two types of integration are found in HPV-associated
neoplasias (Jeon et al., 1995). Type 1 integration events are ones
in which a single copy of the viral genome becomes integrated in
the host chromosome. Type 2 integration events are ones in which
a concatomer of viral genomes integrates into a site within the
host chromosome. In both cases one can ﬁnd situations in which
the integrated viral genomes and neighboring host DNA are
ampliﬁed. In the cases of type 2 integration events, it is oftenfound that only the 3′ most copy of the viral genome (the one that
is disrupted by the integration event) is transcriptionally active.
The other intact copies of the viral genome appear not to give rise
to mRNAs that accumulate in the cells. One contributing reason for
this difference may be that the mRNAs arising from the junction
copy contain 3′UTRs derived from host DNA. These chimeric viral/
host mRNAs were found to be more stable than viral transcripts
arising from the intact viral genome at least in part because the
viral early mRNA 3′ UTR contains an mRNA instability element
(Jeon and Lambert, 1995). Another possible reason, of relevance to
this discussion, is that the internal copies of the viral genome
within the concatomer are transcriptionally silenced. If so, then a
likely cause would be epigenetic silencing. Unfortunately, sufﬁ-
cient attention has not been given to the genomic state of the HPV
genome in most methylation studies, and only one study has
distinguished between type 1 vs type 2 integration events. In that
study utilizing clonal W12 lines derived from the HPV16-positive
CIN (Kalantari et al., 2008a), differences in methylation status were
observed, with type 2 integration events associated with greater
hypermethylation of the LCR. This ﬁnding is consistent with the
hypothesis that internal copies of the viral genome are epigeneti-
cally silenced.
Role of DNA methylation in the control of the function of the
papillomaviral E2 factor
The viral E2 open reading frame encodes for multiple proteins
that regulate the transcription of the viral genome through their
ability to bind speciﬁc palindromic sites on the viral genome called
E2 binding sites (E2BS). E2BS have the consensus sequence
5′-ACCGNNNNCGGT-3′. The Gaston lab demonstrated that methy-
lation of the CpG motifs within E2BS inhibits the binding of E2
protein to its DNA binding site in vitro (Thain et al., 1997). Kim
et al. (2003) subsequently demonstrated that methylation of E2BSs
in the context of reporter plasmids inhibited the transcriptional
transactivation activity of E2 in transfected cells. As mentioned
before, E2 also plays roles both in the initiation of viral DNA
replication, by helping to assemble the viral E1 DNA helicase at the
origin of viral DNA replication, and in partitioning of the viral DNA
to daughter cells during cell division. Both of these activities of E2
also rely upon its ability to bind E2BSs within the LCR, and
therefore also are predicted to be modulated by the methylation
status of the E2BSs, though this has not been directly demon-
strated. Interestingly, in the context of the high risk HPV genomes,
the E2 transcriptional transactivator can play two opposing roles,
one as an activator of transcription of the viral early promoter, and
second as a repressor of transcription from the same promoter. These
differences are thought to reﬂect the occupancy of different E2BSs.
A number of labs have interrogated the methylation status of
E2BS in natural HPV infections and in cell lines derived from those
infections. Two studies investigated the methylation pattern of the
HPV16 genome in clonal cell lines derived from a CIN lesion, the
before-mentioned W12E cells and W12I cells in which the viral
DNA is found integrated into the host genome as type 1 or type
2 integrants (Kalantari et al., 2008a; Kim et al., 2003). In W12E
cells maintained in the undifferentiated state, E2BSs present on
the extrachromosomal viral genomes were frequently found to be
methylated. This would suggest that E2 binding is suppressed in
these cells. However, when these same cells were induced to
undergo terminal differentiation, a condition in which the papil-
lomaviral genome is ampliﬁed and progeny virus is made,
those same E2BSs became unmethylated. A permutation on this
differentiation-dependent changes in methylation status of E2BS
was observed in before-mentioned study by Vinokurova and von
Knebel Doeberitz (2011). Here the investigators again saw the
differentiation-dependent reduction in methylation of CpGs in the
Table 2
Transcription Factor binding and histone modiﬁcations on the HPV18 genome.
Antigen Replicates with Lab
Signal No signal
Transcription factors
AP2-alpha 0 2 SYDH
AP2-gamma 0 2 SYDH
CEBP-beta 2 0 SYDH
cFos 2 0 SYDH
cmyc 1 1 SYDH
E2F1 2 0 SYDH
E2F4 1 1 SYDH
E2F6 0 2 SYDH
Elk1 2 0 SYDH
Elk4 1 1 SYDH
GABP 0 2 HA
IRF3 1 1 SYDH
junD 2 0 SYDH
MafK 2 0 SYDH
Max 2 0 SYDH
MAZ 2 0 SYDH
MXI 2 0 SYDH
NFYA 0 2 SYDH
NFYB 0 2 SYDH
Nrf1 1 1 SYDH
NRSF 1 1 HA
PRDM1 2 0 SYDH
RFX5 2 0 SYDH
Stat1 1 1 SYDH
Stat3 2 0 SYDH
TCF7L2 2 2 SYDH
Tr4 0 2 SYDH
USF2 2 0 SYDH
ZKSCAN 2 0 SYDH
ZNF274 0 2 SYDH
ZZZ3 0 2 SYDH
Pol2 basal factors
TAF1 1 1 HA
E. Johannsen, P.F. Lambert / Virology 445 (2013) 205–212 2095′ and central region of the LCR, however, in the 3′ end, containing
the 3 E2BSs more proximal to the viral early promoter, the E2BSs
became hypermethylated. Such hypermethylation was not appar-
ent in the differentiated W12E cells. The reason for these differ-
ences has not been elucidated; however, one would predict that
the methylation of the E2BSs in the differentiated cells within
naturally arising lesions may release the viral promoter from
E2-mediated transcriptional repression.
E2BS were also found to be methylated in cells derived from
cervical cancers (Bhattacharjee and Sengupta, 2006). Methylation
of E2BS appears to change during neoplastic progression and
depend upon the integration status of the viral genome within
cancers (Chaiwongkot et al., 2013). In cervical lesions, be they
precancers or cancers, in which the viral genome exists in the
extrachromosomal state, E2BS tend be hypermethylated. In cervi-
cal cancers wherein a single copy of the viral genome is integrated
into the host genome (and E2 is presumed lost due to integration),
the E2BS tend to be hypomethylated. And in cervical cancers in
which the viral genome is integrated as a concatomer, most copies
have hypermethylated E2BS, while a minority are hypomethylated.
The consequence of hypermethylation of E2BSs on viral tran-
scription and viral DNA replication may differ depending upon the
location of the four E2BS that are all located within the LCR. Those
more proximal to the viral early promoter and the viral origin
of viral DNA replication are thought to mediate E2-dependent
transcriptional repression, as well as E1-dependent replication.
Consequently, methylation of these promoter proximal sites could
activate transcription of the viral early genes while inhibiting E1-
dependent replication. Binding by E2 to the promoter distal E2BS,
located in the 5′ end of the LCR, has long been thought to mediate
E2 dependent transcriptional transactivation of the viral E2
promoter; however a recent study suggests this may not be the
case (Vinokurova and von Knebel Doeberitz, 2011).TBP1 2 0 SYDH
TFIIF 2 0 SYDH
Pol2 7 0 SYDH, Broad
Pol3 basal factors
Bdp1 0 2 SYDH
Brf1 0 2 SYDH
Brf2 0 2 SYDH
RPC155 0 2 SYDH
TFIIIc 0 2 SYDH
Chromatin structure and DNA repair
CTCF 0 4 Broad, UW
BRCA1 2 0 SYDH
Rad21 2 0 SYDH
SMC3 2 0 SYDH
ZNF143 2 0 SYDH
Chromatin remodeling
BAF155 0 3 SYDH
BAF170 0 3 SYDH
Brg1 1 2 SYDH
CHD2 1 1 SYDH
Ini1 0 3 SYDH
SPT20 1 1 SYDH
Histone modifying enzymes
coREST 2 0 SYDH
Ezh2 0 2 Broad
GCN5 0 2 SYDH
P300 2 0 SYDH
Histone modiﬁcations
H2Ax 0 2 Broad
H3K9me3 0 2 Broad
H3K27me3 0 2 Broad
H4K20me1 0 2 Broad
H3K4me1 2 0 Broad
H3K4me2 2 0 Broad
H3K4me3 2 0 Broad
H3K9Ac 2 0 Broad
H3K27Ac 2 0 BroadAnalysis of ChIP-seq data from studies performed on HeLa cells
The recent application of ChIP-seq and RNA-seq methodologies
to the study of human cancers provides a new opportunity to
identify epigenetic marks on tumor virus genomes, and correlate
these marks with viral gene expression in the context of neoplastic
diseases caused by these viruses. This is particularly true for HPV18
in the context of cervical cancer, because of the abundance of ChIP-
seq and RNA-seq data now available for HeLa cells. This rich
resource is a direct consequence of the fact that HeLa cells have
held historical importance as the standard cell type for the study of
mammalian transcriptional machinery and chromatin, and there-
fore have been used extensively for ChIP-seq studies. We analyzed
the published datasets from HeLa-S3 cells with the goal of deﬁning
the occupancy of histones and transcription factors on the HPV18
genome found integrated in HeLa cells. Data from 123 ChIP-seq and
two RNA-seq experiments were downloaded from the supporting
website of the ENCODE project (Rosenbloom et al., 2012). For each
dataset, we mapped all raw short reads to the reference HPV18
genome [X05015.1], using the Maq rapid aligner (Li et al., 2008).
Mapped reads were used to generate continuous tag sequence
density tracks with Fseq (Boyle et al., 2008) or python scripts
(Heilmann et al., 2012) and displayed on a local installation of the
UCSC genome browser (see Table 2 for summary of results). The
complete data set for the HPV18 genome, assembled from the 145
ChIP-seq and 2 RNA-seq experiments, is available on PAVE.
Histone modiﬁcation state of HPV18 chromatin in HeLa cells
Chromatin immunoprecipitation of histone marks associated
with active transcription (H3K4me1, H3K4me3, H3K9Ac, H3K27Ac,
Table 2 (continued )
Antigen Replicates with Lab
Signal No signal
H3K36me3 2 0 Broad
H3K79me2 2 0 Broad
RNA-seq 2 0 Caltech
H3K27Ac
H3K27me3
H3K36me3
H3K4me1
H3K4me3 
H3K9Ac
H3K9me3
2 kb 
RNA-seq 
TAF1 
TBP 
TFIIF 
Pol II 
Pol II 
2 kb 
Fig. 1. UCSC genome browser windows showing histone modiﬁcations (left panel),
RNAtranscription, and basal transcription factor binding (right panel) on the HPV18
genome in HeLa-S3 cells as determined by ChIP-seq and RNA-seq. HPV annotation
is shown above the ChIP-seq experiments. The long control region (LCR) and
transcriptional start site are located downstream of the L1 and L2 late genes (red
bars) and upstream of the early genes (blue bars). In general, replicates were highly
similar, but for RNA polymerase II, results were more varied and two representative
experiments are shown.
2 kb 
BRCA1 
CTCF 
Rad21 
SMC3 
Fig. 2. Binding of chromatin architecture and DNA repair proteins to the HPV18
genome in HeLa-S3 cells.
CEBP-
E2F1 
Stat1 
Stat3 
Fos 
Jun 
Myc 
ZKSCAN 
USF2 
PRDM1 
NRSF-rep2 
NRSF-rep1 
Max 
Mxi 
2 kb 2 kb 
Fig. 3. ChIP-seq experiments using HeLa-S3 cells conﬁrm binding of transcription
factors known to bind the HPV18 LCR (left panel) and identify novel binding factors
(right panel). All factors were found to bind between the 3 proximal E2 binding
sites and the single upstream E2 site (shown in magenta in the annotation track).
HPV annotation is shown above the ChIP-seq experiments. For most transcription
factors, binding was identiﬁed in both replicates; however, for a few transcription
factors binding was only observed in one experiment (e.g., NRSF).
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right panel). By contrast, ChIP-seq for facultative (H3K27me3) and
constitutive (H3K9me3) heterochromatin marks retrieved only
minimal HPV18 sequences. These results suggest that all of the
HPV18 genomes integrated in HeLa-S3 cells are transcriptionally
active. The H3K4me1 mark was greatest over the long control
region (LCR) and diminished after the transcriptional start site
(TSS). As seen with cell genes, the H3K4me3 and H3K9Ac marks
were enriched at the promoter, but also extended into the ﬁrst
exon. Trimethylation of lysine 36 of histone 3 (H3K36me3),
believed to be important for suppression of cryptic TSSs within
gene (Joshi and Struhl, 2005) extended throughout the transcribed
region. The fact that low signal was observed near the TSS in all of
the histone tracks, suggests that the LCR may be histone depleted.
Although previous studies have suggested this region is organized
into nucleosomes, one possible explanation for apparent discre-
pancy is that extensive transcription factor binding to the LCR
(discussed below) rather than histone binding may account for the
observed nuclease protection of this region (Stunkel and Bernard,
1999). Of note, the abrupt loss of histone marks seen upstream of
the LCR (most obvious at the 5′ end of the H3K36me3 track) and
downstream within E2 correspond to the deletions within the
HPV18 genome that exist within the integrated copies of the
HPV18 genome in HeLa cells (Meissner, 1999).
RNA-seq experiments were consistent with transcription initi-
ating at the viral early (P105) promoter and the transcribed region
extending from just upstream of the E6 gene through most of the
E1 gene (Fig. 1, right panel). This is in good agreement with the E6-
E7-ΔE1 transcript that gives rise to the 3.1 kb mRNA. In both
experiments, the mapped reads were greater over the E6 and E7
genes than E1, likely reﬂecting the presence of the E6n-E7
transcript as well (Inagaki et al., 1988). Binding of the basal
transcription factors TBP, TAF2F, and TAF1 were highest at the
transcriptional start site (TSS) at the P105 promoter. Although RNA
polymerase II signal is typically also highest at the TSS, indicative
of pausing during transcript initiation, high pol II signal was
observed at the TSS as well as multiple downstream sites. This
may indicate rapid assembly of initiation at the LCR or that RNA
polymerase II pausing, possibly regulatory in nature, is also
occurring downstream of the TSS.
Examination of 4 independent ChIP-seq experiments did not
provide any evidence for CTCF binding to the HPV18 genome in
HeLa cells (Fig. 2). The CTCF-associated cohesion complex proteins
Rad21 and SMC3 did bind within the LCR and at the 3′ end of the
genome near the integration site. These proteins have been
implicated in chromosome structure as well as DNA repair.
Another DNA repair protein, BRCA1 was observed to bind at the
LCR. Future studies will be needed to determine if these binding
locations are reﬂective of the chromatin organization of HPV18 in
general or are unique to the integration event in cancer cells in
general or HeLa cells in particular.
Transcription factor occupancy on the HPV18 LCR in HeLa cells
Extensive transcription factor binding was observed in the
central LCR enhancer (Fig. 3). This included well-studied factors
such as AP1 (Jun/Fos), Stat1, E2F1, and CEBP-beta as well aspotentially novel binding factors like Elk1, IRF3, MafK, MAZ,
USF2, and ZKSCAN. Several potential heterodimers can be inferred
to bind, including c-myc/max, Stat1/Stat3, and c-Fos/JunD. MafK
and USF2 are also likely to fall into this category, but their
heterodimerizing partners have not been studied. Interestingly, a
recent study demonstrated that the LCR was highly responsive to
c-myc expression (Sichero et al., 2012) consistent with the results
Nrf1-rep1 
Nrf1-rep2 
2 kb 
Fig. 4. Nuclear Respiratory Factor 1 (NRF1) was the only transcription factor
observed to bind outside the LCR. Binding was observed in replicate 1, but not in
replicate 2. The sequencing artifact in this peak is discussed in the text.
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myc in cervical cancer cells. Because of the resolution of the ChIP-
seq experiments is only about 100 bp, it was only possible to
determine whether a transcription factor bound, but not precisely
where. Indeed, although there are two AP1 sites within the LCR,
both the cFos and JunD ChIP-seq contain only single peak; it is not
clear whether this single peak reﬂects binding to one or both of
the closely spaced sites. Of potential interest is that for some
transcription factors, a strong signal was observed in one ChIP-seq
replicate, but not in the other (see Table 2). These included c-myc,
E2F4, Elk4, IRF3, Nrf1, NRSF, and Stat1 (for example, see Fig. 3,
compare NSRF replicates 1 and 2). Although this may raise doubts
about whether these transcription factors bind to the LCR at all, it
also raises the more interesting possibility that binding of some
transcription factors is dynamic (e.g., dependent upon activation of
stress response pathways or interferon signaling). Further studies
will be needed to determine if these dynamic binding events, if
real, result in signiﬁcant changes in the expression levels of HPV
oncogenes.
One transcription factor, NRF1, was observed to bind outside of
the LCR (Fig. 4). This was only observed in one replicate and the
peak contained a sequencing artifact (column extending from
center of the peak) that corresponded to a G/AT repeat motif at
the 3′ end of the L1 gene. Whether this binding is real and
biologically signiﬁcant remains to be determined. It is worth
noting that this same repeat was found to be expanded in HPV6
wild type genomes, but deleted during expansion of the HPV6
reference strain (Heinzel et al., 1995). A similar expansion of this
repeat in the HPV18 genome integrated into HeLa-S3 cells could
account for the observed sequencing “artifact”.Acknowledgments
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